BVD2-23B6 is an unique therapeutic strategy intended to specifically block patient's granulocyte-macrophage colony-stimulating factor. Engineered by sophisticated molecule creation processes, this therapy shows https://www.targetmol.com/compound/anti-human-gm-csf-antibody-bvd2-23b6